CIK 0000920148
- Large accelerated filer
LABCORP HOLDINGS INC.
Sign in to watch- Ticker
- LH
- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 992588107
- Phone
- +1 336-229-1127
- Business address
- 358 S MAIN ST, BURLINGTON, NC, 27215
- Former names
- LABORATORY CORP OF AMERICA HOLDINGS, NATIONAL HEALTH LABORATORIES HOLDINGS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,377,699
- in 4 filings, $108K under 10b5-1 plans
Net −$1,377,699. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-18 | Schroeder Mark S EVP, Pres Diagnostics & COO | Exercise or conversion · Non-qualified Stock Options 10b5-1 | −1,500 | 1,900 | ||
| 2023-05-05 | Schroeder Mark S EVP, Pres Diagnostics & COO | Grant or award · Non-qualified Stock Options | +1,400 | 1,400 | ||
| 2023-05-05 | Schroeder Mark S EVP, Pres Diagnostics & COO | Grant or award · Restricted Stock Unit | +440 | 3,121 | ||
| 2023-05-05 | Caveney Brian J EVP, Pres of ED, CMO & CSO | Grant or award · Non-qualified Stock Options | +1,000 | 1,000 | ||
| 2023-05-05 | Caveney Brian J EVP, Pres of ED, CMO & CSO | Grant or award · Restricted Stock Unit | +300 | 2,981 | ||
| 2023-05-05 | Bailey Megan D. EVP, Chief Strategy Officer | Grant or award · Restricted Stock Unit | +180 | 4,807 | ||
| 2023-05-05 | Bailey Megan D. EVP, Chief Strategy Officer | Grant or award · Non-qualified Stock Options | +600 | 600 | ||
| 2023-05-05 | DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl | Grant or award · Non-qualified Stock Options | +1,200 | 1,200 | ||
| 2023-05-05 | DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl | Grant or award · Restricted Stock Unit | +370 | 1,664 | ||
| 2023-04-05 | GRAHAM ANITA Z EVP, CHRO | Grant or award · Non-qualified Stock Options | +3,000 | 3,000 | ||
| 2023-04-05 | GRAHAM ANITA Z EVP, CHRO | Grant or award · Restricted Stock Unit | +990 | 990 | ||
| 2023-03-31 | Schroeder Mark S EVP, President-Diagnostics Lab | Sale 10b5-1 | −3,897 | $225.81 | $880K | 6,687.4 |
| 2023-03-30 | Schechter Adam H President & CEO | Grant or award | +42,353 | 65,534 | ||
| 2023-03-30 | Schechter Adam H President & CEO | Shares withheld for taxes | −18,646 | $224.70 | $4.2M | 46,888 |
| 2023-03-30 | Kirchgraber Paul R CEO, Covance Drug Development | Grant or award | +6,763 | 15,832 | ||
| 2023-03-30 | Kirchgraber Paul R CEO, Covance Drug Development | Shares withheld for taxes | −2,886 | $224.70 | $648K | 12,946 |
| 2023-03-30 | EISENBERG GLENN A Chief Financial Officer, EVP | Grant or award | +11,715 | 47,355 | ||
| 2023-03-30 | EISENBERG GLENN A Chief Financial Officer, EVP | Shares withheld for taxes | −5,179 | $224.70 | $1.2M | 42,176 |
| 2023-03-30 | Caveney Brian J EVP, President of Diagnostics | Grant or award | +6,763 | 23,175.76 | ||
| 2023-03-30 | Caveney Brian J EVP, President of Diagnostics | Shares withheld for taxes | −2,990 | $224.70 | $672K | 20,185.76 |
Page 37 of 41 · 816 trades